- Home
- HFBL vs QNCX Comparison
HFBL vs QNCX Comparison
Compare HFBL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- QNCX
- Stock Information
- Founded
- HFBL 1924
- QNCX 2012
- Country
- HFBL United States
- QNCX United States
- Employees
- HFBL N/A
- QNCX N/A
- Industry
- HFBL Savings Institutions
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HFBL Finance
- QNCX Health Care
- Exchange
- HFBL Nasdaq
- QNCX Nasdaq
- Market Cap
- HFBL 41.3M
- QNCX 47.7M
- IPO Year
- HFBL N/A
- QNCX 2019
- Fundamental
- Price
- HFBL $13.25
- QNCX $1.61
- Analyst Decision
- HFBL
- QNCX Strong Buy
- Analyst Count
- HFBL 0
- QNCX 6
- Target Price
- HFBL N/A
- QNCX $8.17
- AVG Volume (30 Days)
- HFBL 847.0
- QNCX 207.3K
- Earning Date
- HFBL 07-29-2025
- QNCX 08-19-2025
- Dividend Yield
- HFBL 3.78%
- QNCX N/A
- EPS Growth
- HFBL 6.78
- QNCX N/A
- EPS
- HFBL 1.26
- QNCX N/A
- Revenue
- HFBL $20,802,000.00
- QNCX N/A
- Revenue This Year
- HFBL N/A
- QNCX N/A
- Revenue Next Year
- HFBL N/A
- QNCX N/A
- P/E Ratio
- HFBL $10.40
- QNCX N/A
- Revenue Growth
- HFBL 1.50
- QNCX N/A
- 52 Week Low
- HFBL $11.75
- QNCX $0.51
- 52 Week High
- HFBL $14.25
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- HFBL 48.38
- QNCX 47.34
- Support Level
- HFBL $13.52
- QNCX $1.55
- Resistance Level
- HFBL $13.40
- QNCX $1.75
- Average True Range (ATR)
- HFBL 0.07
- QNCX 0.11
- MACD
- HFBL -0.04
- QNCX -0.03
- Stochastic Oscillator
- HFBL 45.65
- QNCX 20.00
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.